Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • Innovent Biologics

This publication has 40 references indexed in Scilit: